We claim:

1. A combination comprising a first agent that is a Smoothened inhibitor and a second agent that is an mTOR inhibitor,
wherein the first agent is 2-[(R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-yl]-propan-2-ol or a pharmaceutically acceptable salt thereof.

2. The combination of claim 1, wherein said second agent is an mTOR allosteric inhibitor active against the mTORC1 complex or an ATP competitive mTOR inhibitors active against the mTORC1 and mTORC2 complexes.

3. The combination of claim 1, wherein said second agent is selected from the group consisting of AY-22989, everolimus, CCI-779, AP-23573, MK-8669, AZD-8055, Ku-0063794, OSI-027, WYE-125132.

4. The combination of claim 3, wherein the second agent is everolimus.

5. The use of the combination of any one of claims 1-4, for the treatment of a cancer related to the Hedgehog pathway or mTOR.

6. The use of claim 5, wherein the cancer is medulloblastoma.

7. The use of a combination to treat medulloblastoma, wherein the combination comprises a first agent that is a Smoothened inhibitor and a second agent that is an mTOR inhibitor,
wherein the first agent is 2-methyl-4'-trifluoromethoxy-biphenyl-3-carboxylic acid [6-(cis-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide or a pharmaceutically acceptable salt thereof.

8. The use of claim 7, wherein said second agent is an mTOR allosteric inhibitor active against the mTORC1 complex or an ATP competitive mTOR inhibitors active against the mTORC1 and mTORC2 complexes.

9. The use of claim 7, wherein said second agent is selected from the group consisting of AY-22989, everolimus, CCI-779, AP-23573, MK-8669, AZD-8055, Ku-0063794, OSI-027, WYE-125132.

10. The use of claim 9, wherein the second agent is everolimus.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A pharmaceutical composition comprising a first agent that is a Smoothened inhibitor and a second agent that is an mTOR inhibitor,
wherein the first agent is 2-[(R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[l,2']bipyrazinyl-5'-yl]-propan-2-ol or a pharmaceutically acceptable salt thereof.

2. The use of a combination for the manufacture of a medicament for treating medulloblastoma, wherein the combination comprises a first agent that is a Smoothened inhibitor and a second agent that is an mTOR inhibitor,
wherein the first agent is 2-methyl-4'-trifluoromethoxy-biphenyl-3-carboxylic acid [6-(cis-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide or a pharmaceutically acceptable salt thereof.

3. The use of claim 2, wherein said second agent is an mTOR allosteric inhibitor active against the mTORCI complex or an ATP competitive mTOR inhibitors active against the mTORCI and mTORC2 complexes.

4. The use of claim 2, wherein said second agent is selected from the grottp consisting of AY-22989, everolimus, CCI-779, AP-23573, MK-8669, AZD-8055, Ku-0063794, OSI-027, WYE-125132.

5. The use of claim 4, wherein the second agent is everolimus.